Azilsartan Kamedoxomil is a combination antihypertensive agent composed of azilsartan, an angiotensin II receptor blocker (ARB), and kamedoxomil, a prodrug metabolized into an active metabolite. It is marketed under various brand names globally.
Supply Highlights: Takeda is the primary global supplier of azilsartan-based medications, including combination formulations with kamedoxomil. It holds key patents and licenses for these drugs in several markets.
2. Farmindustria (Italy) and Other Generics Suppliers
Supply Highlights: Several local companies produce generic versions of azilsartan and combination drugs with kamedoxomil. These companies typically obtain licensing arrangements or utilize patent expirations.
Supply Highlights: While primarily offering generic azilsartan, Teva may provide combination drugs depending on regional regulatory approvals.
4. Other Regional Suppliers
Various companies in regions like India, China, and South Korea manufacture generic versions, including:
Zhejiang Huahai Pharmaceutical (China)
Hetero Labs (India)
Aurobindo Pharma (India)
These companies often supply APIs and finished dosage forms to global markets, contingent on regulatory compliance.
Supply Chain Dynamics and Licensing Agreements
Patent Status: In many territories, azilsartan Kamedoxomil is protected by patents held by Takeda, restricting generic entry until patent expiration. Patent expiry generally occurred around 2028 in major markets.
Regulatory Approvals: Suppliers secure approvals from agencies such as the FDA (U.S.), EMA (Europe), and others to market generic or branded versions.
API and Finished Dose Production
Active Pharmaceutical Ingredient (API): Suppliers like Zhejiang Huahai, Hetero Labs, and Aurobindo produce APIs for both azilsartan and kamedoxomil.
Finished Dosage Forms: Typically manufactured by contract manufacturing organizations (CMOs) under licensing agreements or via Takeda's in-house facilities for branded products.
Distribution and Market Penetration
Breaking down regional supply:
United States: Takeda (branded), multiple generics
Europe: Takeda, regional generics
Asia: Significant presence of regional suppliers, especially India and China
Emerging Markets: Growing access via regional generics and imports
Summary of Key Suppliers
Supplier
Product Focus
Region
Licensing/Patents
Notes
Takeda
Branded & Generics
Global
Has patents until ~2028
Primary innovator and patent holder
Hetero Labs
APIs and generics
India
Patent expired or license-dependent
Major regional generic supplier
Zhejiang Huahai
APIs
China
Active in the market
Supplies APIs for multiple markets
Aurobindo Pharma
APIs & Generics
India
Regional patents/license agreements
Supplies APIs and finished formulations
Regulatory Considerations
Biosimilar and Generic Entry: Patents limit generic manufacturing until expiry; approval depends on clinical equivalence.
Quality Standards: Suppliers must adhere to regulatory standards like WHO GMP, FDA, and EMA certifications.
Key Takeaways
Takeda dominates global supply with its branded product Edarbi, holding patents until approximately 2028.
Multiple regional suppliers produce APIs and generics, especially in India and China.
Licensing agreements and patent protections are critical in determining market access.
The global supply chain includes both branded manufacturer Takeda and various regional generic producers.
Regulatory approval, patent status, and regional policies influence supply availability.
FAQs
Who are the main suppliers of azilsartan Kamedoxomil?
Takeda Pharmaceuticals is the primary global supplier; regional generics include Aurobindo and Hetero Labs.
When will patent restrictions for azilsartan Kamedoxomil expire?
Approximate patent expiration in major markets occurs around 2028, enabling potential generic entry.
Which regions have the most generic suppliers?
India and China have the highest number of API producers and generic manufacturers for azilsartan-based drugs.
Are there licensed generics available?
Yes, generics are available via licensing agreements or once patents expire, subject to regional approval.
What role do APIs play in the supply chain?
APIs are produced primarily in China and India, then formulated into finished dosage forms in various regions depending on market access.
References
[1] U.S. Food and Drug Administration. (2021). Approved Drugs: Edarbi (azilsartan medoxomil).
[2] European Medicines Agency. (2022). Summary of Product Characteristics for Edarbi.
[3] Patent data for azilsartan in the U.S. and EU (2022).
[4] Leading Indian pharmaceutical companies' annual reports, 2022.
[5] Market supply chain insights from IQVIA, 2022.
